4/30
01:19 pm
dcph
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) had its "neutral" rating re-affirmed by analysts at Guggenheim.
Low
Report
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) had its "neutral" rating re-affirmed by analysts at Guggenheim.
4/30
01:19 pm
dcph
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) had its "neutral" rating re-affirmed by analysts at Guggenheim.
Low
Report
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) had its "neutral" rating re-affirmed by analysts at Guggenheim.
4/30
01:01 pm
dcph
Rating for DCPH
Low
Report
Rating for DCPH
4/30
01:01 pm
dcph
Rating for DCPH
Low
Report
Rating for DCPH
4/30
12:10 pm
dcph
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) had its "market perform" rating re-affirmed by analysts at JMP Securities.
Low
Report
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) had its "market perform" rating re-affirmed by analysts at JMP Securities.
4/30
12:10 pm
dcph
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) had its "market perform" rating re-affirmed by analysts at JMP Securities.
Low
Report
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) had its "market perform" rating re-affirmed by analysts at JMP Securities.
4/30
11:57 am
dcph
Rating for DCPH
Low
Report
Rating for DCPH
4/30
11:57 am
dcph
Rating for DCPH
Low
Report
Rating for DCPH
4/30
09:07 am
dcph
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $26.00 price target on the stock, up previously from $9.00.
Low
Report
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $26.00 price target on the stock, up previously from $9.00.
4/30
08:51 am
dcph
Rating for DCPH
Low
Report
Rating for DCPH
4/30
08:51 am
dcph
Rating for DCPH
Low
Report
Rating for DCPH
4/29
11:12 am
dcph
Rating for DCPH
Low
Report
Rating for DCPH
4/29
11:12 am
dcph
Rating for DCPH
Low
Report
Rating for DCPH